Inicio › Carcinoma de células escamosas de cabeza y cuello › California › Irvine
Ensayos clínicos de Carcinoma de células escamosas de cabeza y cuello en Irvine, CA
11 estudios para Carcinoma de células escamosas de cabeza y cuello buscan participantes en centros de Irvine y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
ReclutandoFase 1
- City of Hope at Irvine Lennar, Irvine
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
ReclutandoFase 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
ReclutandoFase 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
ReclutandoFase 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
ReclutandoFase 1/2
- City of Hope, Irvine, Irvine
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
ReclutandoFase 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
ReclutandoFase 1
- City of Hope at Irvine Lennar, Irvine
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
ReclutandoFase 1
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278432, Irvine
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
ReclutandoFase 1
- Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
ReclutandoFase 1
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589, Irvine
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
ReclutandoFase 1/2
- University of California, Irvine, Irvine
Ensayos de Carcinoma de células escamosas de cabeza y cuello en otras ciudades
- Houston, TX47 estudios
- Los Angeles, CA42 estudios
- Boston, MA40 estudios
- Nashville, TN39 estudios
- New York City, NY39 estudios
- St. Louis, MO28 estudios
- Arlington, VA26 estudios
- Chicago, IL26 estudios
- Philadelphia, PA26 estudios
- Atlanta, GA24 estudios
- San Antonio, TX22 estudios
- Pittsburgh, PA22 estudios
Otros estudios en Irvine
- Cáncer de pulmón de células no pequeñas25 estudios
- Cáncer de seno23 estudios
- Cáncer (todos los tipos)17 estudios
- Cáncer metastásico16 estudios
- Cáncer de pulmón15 estudios
- Mieloma múltiple14 estudios
- Cáncer de próstata14 estudios
- Cáncer de ovario12 estudios
- Cáncer de vejiga11 estudios
- Enfermedad de Alzheimer11 estudios
- Cáncer del colon y del recto10 estudios
- Cáncer de páncreas10 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.